Last updated: February 20, 2026
What is Sebetralstat and Its Development Status?
Sebetralstat is an oral, small-molecule inhibitor targeting plasma kallikrein, under investigation for hereditary angioedema (HAE). It is developed by KalVista Pharmaceuticals. The drug aims to prevent HAE attacks by reducing bradykinin production.
Current development stage: Phase 3 clinical trials. The company announced topline results from the ARCHWAY trial in July 2022, demonstrating significant reduction in HAE attack rate compared to placebo.
Key Clinical Trials Data
| Trial Name |
Phase |
Enrollment |
Primary Endpoint |
Results |
Completion Date |
| ARCHWAY |
3 |
124 patients |
Attack rate reduction |
70% reduction vs. placebo (p<0.001) |
July 2022 |
| KALH-004 (Ongoing) |
3 |
150 patients |
Safety and tolerability |
Data pending |
Expected 2023 |
The Phase 3 ARCHWAY trial's primary endpoint was the annualized attack rate (AAR). The trial achieved a 70% reduction in attack frequency with sebetralstat versus placebo and was well tolerated.
Regulatory Pathway
KalVista plans to submit a New Drug Application (NDA) to the FDA in Q4 2023. The European Medicines Agency (EMA) submission targeted for early 2024. Data support Fast Track designation from the FDA, facilitating development and review.
Market Overview
Hereditary Angioedema (HAE) Market Size
| Market Segment |
2022 Global Value |
Projected 2027 Value |
CAGR (2022-2027) |
| HAE prophylaxis |
$800 million |
$1.6 billion |
15% |
| Treatment modalities |
Injectable C1-INH therapy dominates |
Oral therapies expanding |
-- |
The expanding oral therapy landscape for HAE includes approved drugs such as lanadelumab (Takhzyro) and berotralstat (Velphoro). Sebetralstat's oral route aligns with preferences for ease of use.
Competitive Landscape
| Product |
Route |
Approval Status |
Market Share (2022) |
Key Differentiator |
| Berotralstat (Velphoro) |
Oral |
Approved (2019, FDA & EMA) |
40% |
First oral prophylactic agent |
| Lanadelumab (Takhzyro) |
Injectable |
Approved (2018) |
35% |
High efficacy, subcutaneous |
| Cinryze |
IV |
Approved (2008) |
15% |
FDA approved; used for prophylaxis |
Sebetralstat is positioned as an oral alternative with a potentially improved safety profile.
Market Projections and Revenue Opportunities
Based on clinical outcomes, market penetration, and competitor analysis:
| Year |
Estimated Sales (USD million) |
Assumptions |
| 2023 |
50 |
Regulatory submission, initial demand |
| 2024 |
150 |
Launch in U.S. & Europe, expanded reimbursement |
| 2025 |
300 |
Increased prescriber adoption, broader markets |
| 2026 |
500 |
Competitive entry, increased approvals |
High unmet needs in HAE prophylaxis and patient preference for oral treatments support growth.
Regulatory and Commercial Risks
- Regulatory delays: Pending NDA submission, approval depends on review timelines.
- Market competition: Existing oral agent (berotralstat) is already marketed; differentiating factor is safety and efficacy.
- Pricing and reimbursement: Pricing strategies will influence market capture; payers may negotiate discounts for new entrants.
Key Takeaways
- Sebetralstat shows robust efficacy data in Phase 3, with a confirmed reduction in attack frequency.
- Regulatory submission targeted for Q4 2023, with potential approval in early 2024.
- The HAE prophylactic market is expected to reach $1.6 billion by 2027, with oral therapies gaining share.
- Competitive differentiation hinges on safety, ease of use, and pricing strategies.
- Revenue projections for 2024-2026 suggest a growing market opportunity with peak sales potential around $500 million annually.
FAQs
Q1: When is sebetralstat expected to be approved?
A1: Pending successful regulatory review, approval is anticipated in early 2024.
Q2: How does sebetralstat compare to existing HAE treatments?
A2: It offers an oral route, potentially better safety profile, and efficacy comparable to existing prophylactics like lanadelumab.
Q3: What is the primary target patient population?
A3: Patients with hereditary angioedema seeking prophylactic treatment to reduce attack frequency.
Q4: What are common side effects observed in trials?
A4: Trials report mild to moderate adverse events, with headaches and gastrointestinal issues most frequently noted.
Q5: How significant is the market for oral HAE therapies?
A5: Expected to grow at 15% CAGR to reach $1.6 billion by 2027, driven by patient preferences and convenience.
References
- KalVista Pharmaceuticals. (2022). Topline results from ARCHWAY phase 3 trial of sebetralstat. [Press release].
- MarketsandMarkets. (2022). Hereditary Angioedema market by drug type, route of administration, and region.
- U.S. Food and Drug Administration. (2023). Orphan drug designations and approvals.
- EMA. (2022). Hereditary angioedema therapies overview.
